Juniper Pharmaceuticals (Nasdaq: JNP) address unmet and underserved medical needs in women's health. Our product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:
- JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
- JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
- JNP-0301, a natural progesterone IVR for the prevention of preterm birth.
Our R&D programs are supported by cash flow generated by Crinone® (progesterone gel) and Juniper Pharma Services ("JPS"). We supply Crinone to Merck KGaA, Darmstadt, Germany, for sale outside the US. JPS provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing services manufacturing to clients while concurrently advancing our internal product candidates.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and Allergan, Inc. in the U.S.